Menu
Search
|

Menu

Close
X

Immunomedics Inc IMMU.OQ (NASDAQ Stock Exchange Global Market)

16.72 USD
+1.00 (+6.36%)
As of Sep 13
Previous Close 15.72
Open 15.77
Volume 782,838
3m Avg Volume 790,110
Today’s High 16.87
Today’s Low 15.77
52 Week High 24.99
52 Week Low 11.57
Shares Outstanding (mil) 125.38
Market Capitalization (mil) 1,461.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.91 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
1
FY17
3
FY16
3
EPS (USD)
FY19
-0.853
FY18
-1.335
FY17
-1.437
FY16
-0.623
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
472.92
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
-367.82
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Behzad Aghazadeh
Executive Chairman of the Board, Since 2019
Salary: --
Bonus: --
Usama Malik
Chief Financial Officer, Since 2019
Salary: $185,000.00
Bonus: --
Kurt Andrews
Chief Human Resource Officer, Since 2018
Salary: $145,660.00
Bonus: --
Morris Rosenberg
Chief Technology Officer, Since 2018
Salary: --
Bonus: --
William Fricker
Principal Accounting Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 the American Rd
MORRIS PLAINS   NJ   07950-2460

Phone: +1973.6058200

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

SPONSORED STORIES